title: Performance of the HEMORR 2 HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in nonwarfarin anticoagulated atrial fibrillation patients.
authors.forename: Stavros
authors.initials: S
authors.lastname: Apostolakis
authors.forename: Deirdre A
authors.initials: DA
authors.lastname: Lane
authors.forename: Yutao
authors.initials: Y
authors.lastname: Guo
authors.forename: Harry
authors.initials: H
authors.lastname: Buller
authors.forename: Gregory Y H
authors.initials: GY
authors.lastname: Lip
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000009:adverse effects*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009844:Oligosaccharides / Q000627:therapeutic use; D017063:Outcome Assessment, Health Care; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D018570:Risk Assessment
chemical_list: D000925:Anticoagulants; D009844:Oligosaccharides; C479958:idraparinux